Overview

Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis

Status:
Completed

Trial end date:
2020-06-30

Target enrollment:
0

Participant gender:
All

Summary

This study aims to evaluate the efficacy of pirfenidone in chronic hypersensitivity pneumonitis. This study included 40 adult patients (≥ 18 years) with a diagnosis of chronic progressive hypersensitivity pneumonitis. The included patients were divided into 2 groups 20 patients in each one. Group 1: will receive pirfenidone in addition to the conventional treatment Group 2: will be maintained on conventional treatment. Forced vital capacity (FVC),6 minutes walking test(6MWT), oxygen tension in the arterial blood (PaO2), and St. George's Respiratory Questionnaire (SGRQ ) were measured before and after 6 months of a pirfenidone treatment trial. Results

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Zagazig University

Treatments:

Pirfenidone

Criteria

Inclusion Criteria:

- Patients ≥ 18 years old with a diagnosis of chronic progressive Hypersensitivity
pneumonitis:

- >10% extent of fibrosis (eg, reticulation) on high-resolution CT (HRCT) scan

- Absolute decline in FVC% predicted >5% within the previous 6 months despite
conventional treatment.

Exclusion Criteria:

- Pregnancy or breastfeeding period

- Patients with peptic ulcer, severe hepatic disease, severe kidney disease, severe
cardiac disease, and patients with other chronic pulmonary diseases.

- Presence of active infection

- History of alcohol or drugs abuse

- Active smokers